On November 3, 2026 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that new preclinical data on PoxSTG-EEV, its novel enveloped chimeric oncolytic virus, have been selected for a poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting. SITC (Free SITC Whitepaper) will take place November 4 – 8, 2026, in Phoenix, Arizona (USA).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These data highlight the potential of PoxSTG-EEV, a next-generation chimeric oncolytic virus with a novel Extracellular Enveloped Virion (EEV) formulation developed by Transgene to enhance intratumoral dissemination and increase resistance to immune-mediated neutralization, supporting its potential for systemic (IV) administration.
"Oncolytic viruses have shown considerable promise in cancer treatment, however their full therapeutic potential could be further enhanced by improvements related to systemic delivery and intratumoral spread," said Katell Bidet-Huang, Chief Scientific Officer ad interim at Transgene. "These preclinical findings demonstrate the potential of PoxSTG-EEV to address some of these barriers and highlight the continued innovation from Transgene’s viral vector expertise."
"PoxSTG-EEV combines the PoxSTG chimeric viral vector backbone, with an EEV-enriched formulation designed to generate and preserve the EEV form of the virus and serves as the backbone for Transgene’s proprietary EEVOLVTM platform, supporting the development of a new generation of poxvirus-based-clinical candidates" added Johann Foloppe, PhD, Senior scientist and Project leader at Transgene.
Preclinical studies showed that compared with conventional oncolytic vaccinia viruses, PoxSTGEEV enhanced cytotoxic activity across multiple tumor cell lines and intratumoral dissemination, while maintaining infectivity in the presence of active complement and neutralizing antibodies. In mouse models, intravenous administration significantly reduced tumor growth and prolonged survival.
Poster Details
Title: "PoxSTG-EEV: a Novel Enveloped Virion – Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery"
• Abstract number: 1050
• Date: November 7, 2026
• Authors: Johann Foloppe, Juliette Kempf, Michèle Klein, Julie Hortelano, Baptiste Moreau,
Laurine Gault, Isabelle Farine, Philippe Erbs
The poster will be available on the websites of SITC (Free SITC Whitepaper) and Transgene on November 7, 2026, at 9:00 a.m. ET.
(Press release, Transgene, NOV 3, 2026, View Source [SID1234674094])